Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics Statistics
Share Statistics
Celldex Therapeutics has 66.38M shares outstanding. The number of shares has increased by 0.72% in one year.
Shares Outstanding | 66.38M |
Shares Change (YoY) | 0.72% |
Shares Change (QoQ) | 0.06% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 64.7M |
Failed to Deliver (FTD) Shares | 30K |
FTD / Avg. Volume | 3.42% |
Short Selling Information
The latest short interest is 8.48M, so 12.78% of the outstanding shares have been sold short.
Short Interest | 8.48M |
Short % of Shares Out | 12.78% |
Short % of Float | 13.11% |
Short Ratio (days to cover) | 7.86 |
Valuation Ratios
The PE ratio is -10.31 and the forward PE ratio is -7.39. Celldex Therapeutics's PEG ratio is 0.64.
PE Ratio | -10.31 |
Forward PE | -7.39 |
PS Ratio | 231.8 |
Forward PS | 1.6 |
PB Ratio | 2.18 |
P/FCF Ratio | -10.31 |
PEG Ratio | 0.64 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Celldex Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.91, with a Debt / Equity ratio of 0.01.
Current Ratio | 18.91 |
Quick Ratio | 18.91 |
Debt / Equity | 0.01 |
Debt / EBITDA | -0.02 |
Debt / FCF | -0.02 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $37.74K |
Profits Per Employee | $-848.73K |
Employee Count | 186 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -56.75% in the last 52 weeks. The beta is 1.76, so Celldex Therapeutics's price volatility has been higher than the market average.
Beta | 1.76 |
52-Week Price Change | -56.75% |
50-Day Moving Average | 21.52 |
200-Day Moving Average | 29.55 |
Relative Strength Index (RSI) | 33.94 |
Average Volume (20 Days) | 877.61K |
Income Statement
In the last 12 months, Celldex Therapeutics had revenue of 7.02M and earned -157.86M in profits. Earnings per share was -2.45.
Revenue | 7.02M |
Gross Profit | 7.02M |
Operating Income | -195.08M |
Net Income | -157.86M |
EBITDA | -191.9M |
EBIT | -195.08M |
Earnings Per Share (EPS) | -2.45 |
Balance Sheet
The company has 28.36M in cash and 3.81M in debt, giving a net cash position of 24.54M.
Cash & Cash Equivalents | 28.36M |
Total Debt | 3.81M |
Net Cash | 24.54M |
Retained Earnings | -1.56B |
Total Assets | 792.34M |
Working Capital | 707.66M |
Cash Flow
In the last 12 months, operating cash flow was -157.78M and capital expenditures 0, giving a free cash flow of -157.78M.
Operating Cash Flow | -157.78M |
Capital Expenditures | 0 |
Free Cash Flow | -157.78M |
FCF Per Share | -2.45 |
Margins
Gross margin is 100%, with operating and profit margins of -2778.89% and -2248.76%.
Gross Margin | 100% |
Operating Margin | -2778.89% |
Pretax Margin | -2248.76% |
Profit Margin | -2248.76% |
EBITDA Margin | -2733.63% |
EBIT Margin | -2778.89% |
FCF Margin | -2247.55% |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for CLDX is $46, which is 163.6% higher than the current price. The consensus rating is "Buy".
Price Target | $46 |
Price Target Difference | 163.6% |
Analyst Consensus | Buy |
Analyst Count | 8 |
Stock Splits
The last stock split was on Feb 11, 2019. It was a backward split with a ratio of 1:15.
Last Split Date | Feb 11, 2019 |
Split Type | backward |
Split Ratio | 1:15 |
Scores
Altman Z-Score | 13.47 |
Piotroski F-Score | 3 |